COVID-19 mRNA Vaccines

Mechanism of Action for:

- Moderna COVID-19 Vaccine (mRNA-1273)
- Pfizer BioNTech COVID-19 Vaccine (BNT-162b2)

David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington





Acknowledgments and Permission

The *mRNA Vaccine Slide Set* is a collaborative effort between the University of Washington Infectious Diseases Education and Assessment (IDEA) Program and Cognition Studio, Inc.

Project Design and Content Development

David Spach, MD (University of Washington) and Cognition Studio, Inc.

Content Development and Medical Illustrations

- □ Inessa Stanishevskaya, MScBMC, CMI (Cognition Studio, Inc.)
- Regina Milner, MS (Cognition Studio, Inc.)
- David Ehlert, MAMS, CMI, FAMI (Cognition Studio, Inc.)
- The *mRNA Vaccine Slide Set* is licensed under a Creative Commons Attribution 4.0 International License.
- No permission is required, reusers may distribute or adapt the material for noncommercial purposes only, and must include the following attribution:

University of Washington IDEA Program: COVID-19 Treatment (https://covid.idea.medicine.uw.edu)



Slides WITH Text




DNA versus RNA

- To understand mRNA vaccines it is important to understand fundamental differences between DNA and RNA
- DNA has two backbone strands whereas RNA usually has only one strand
- DNA functions to encode, store, and replicate genetic information
- RNA coverts the genetic code information contained in the DNA to proteins
- RNA contains the uracil base pair in place of the thymidine base pair used in DNA

Deoxyribonucleic acid (DNA)


Ribonucleic acid (RNA)





Basic Flow of Genetic Information for Protein Formation in Humans


- In human cells, the flow of genetic information to protein formation is DNA to RNA to protein
- DNA replication is the process whereby identical copies of the original DNA are made and this occurs in the nucleus of the cell
- Transcription occurs in the nucleus and it is the first step in protein synthesis: an RNA copy is made from DNA and the RNA then moves into the host cytoplasm
- Translation is the process by which mRNA is decoded in the process of protein synthesis and this occurs in the cell cytoplasm





Ribosome Structure and Function


- The ribosome is made up of about 2/3 rRNA and 1/3 proteins
- Each ribosome has a large and small subunit
- The ribosome provides template slots for the sequential addition of the amino acids in the formation of the polypeptide protein precursor
- The ribosome also functions as an enzyme that catalyzes the reaction needed to link amino acids together






Types of RNA

- The three most common types of ribonucleic acid (RNA) are:
 - messenger RNA (mRNA)
 - transfer RNA (tRNA)
 - ribosomal RNA (rRNA)
- The RNAs play an essential role in protein production
- mRNA carries the genetic information from the nucleus to make proteins in the cytoplasm
- tRNA connects mRNA with the amino acids encoded by the mRNA codon
- rRNA is the main structural functional component of the ribosome and it serves to catalyze reactions








SARS-CoV-2 Virus Structure


- SARS-CoV-2 is a single-stranded RNA enveloped virus
- The spike protein is the major surface protein on SARS-CoV-2 and it plays a key role in binding to the host cell receptors
- The spike protein is the primary target of the host immune response to SARS-CoV-2 infection
- Spike protein is an optimal immunologic target to use for COVID-19 vaccines






COVID-19 mRNA Vaccines

- COVID-19 mRNA vaccines consist of mRNA surrounded by a lipid nanoparticle (LNP)
- The LNP has two main functions:
 - 1. Protect the mRNA from being degraded and destroyed
 - 2. Facilitate cellular uptake of the mRNA
- The coding region (orange) is a genetically engineered sequence of nucleoside modified mRNA that encodes for the prefusionstabilized SARS-CoV-2 spike protein
- The Cap 5' and 3' UTR elements enhance the stability and translation of the mRNA




COVID-19 mRNA Vaccines

- This is a simplified view of the lipid nanoparticle (LNP) that surrounds the mRNA
- The LNP has two main functions:
 1. Protect the mRNA from being degraded and destroyed
 - 2. Facilitate cellular uptake of the mRNA
- The coding region (orange) is a genetically engineered sequence of nucleoside modified mRNA that encodes for the prefusionstabilized SARS-CoV-2 spike protein
- The Cap 5' and 3' UTR elements enhance the stability and translation of the mRNA



COVID-19 mRNA Vaccine Delivery

- The mRNA vaccines—Moderna COVID-19 Vaccine (mRNA-1273) and Pfizer-BioNTech COVID-19 (BNT-162b2)—are administered as intramuscular injections
- Both of the mRNA vaccines require 2 doses
- Moderna COVID-19 Vaccine
 - Give 2 doses (each 0.5 mL)
 - Give 1 month (28 days) apart
 - Each dose contains 100 μg mRNA
- Pfizer-BioNTech COVID-19 Vaccine
 - Give 2 doses (each dose 0.3 mL)
 - Give 3 weeks (21 days) apart
 - Each dose contains 30 μg mRNA
- The vaccines should not be interchanged




edit: Cognition Studio, Inc.




Moderna COVID-19 Vaccine (mRNA-1273): Mechanism of Action

- The mRNA-1273 enters the cell cytoplasm and does not enter the nucleus
- The mRNA is non-replicating and is present transiently within the cell
- The mRNA is translated by the ribosomes to form prefusionstabilized SARS-CoV-2 spike proteins
- The spike proteins are shuttled to the surface of the cell and are presented to the immune system
- The spike proteins are also processed into small peptides that also are presented to the immune system




Pfizer-BioNTech COVID-19 Vaccine (BNT-162b2): Mechanism of Action

- The BNT-162b2 mRNA enters the cell cytoplasm and does not enter the nucleus
- The mRNA is non-replicating and is present transiently within the cell
- The mRNA is translated by the ribosomes to form prefusionstabilized SARS-CoV-2 spike proteins
- The spike proteins are shuttled to the surface of the cell and are presented to the immune system
- The spike proteins are also processed into small peptides that also are presented to the immune system



Immune Response to COVID-19 mRNA Vaccines

- The immune system responds to the antigens on the surface of the cell produced by the COVID-19 mRNA vaccines
- The vaccines generate cellular immune responses (T-cell) and and humoral responses (B-cell)
- The immune response includes:
 - 1. Activation of cytotoxic CD8⁺ T cells that can destroy cells infected with SARS-CoV-2
 - Activation of CD4⁺ T cells that augment both CD8⁺ T-cell and B-cell responses
 - 3. Generation of memory T and B cells that can quickly respond to future SARS-CoV-2 infection
 - 4. Activation of B cells to produce antibodies against SARS-CoV-2





Moderna COVID-19 Vaccine (mRNA-1273)

Indication

- Investigational (Not approved by U.S. FDA)
- Authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) in individuals 18 years of age and older

• Dosing and Schedule

- Administer intramuscularly as a series of two doses (0.5 mL each) 1 month apart

Vaccine Storage (See EAU Fact Sheet* for Details)

- Multiple-dose vials are stored frozen between -25° to -15°C (-13° to 5°F)
- Do not store on dry ice or at temperatures below -40°C (-40°F)
- Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use
- Store in original carton to protect from light
- Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours
- After first dose withdrawn, keep vial between 2° to 25°C (36° to 77°F) and discard vial after 6 hours and do not refreeze

Pfizer-BioNTech COVID-19 Vaccine (BNT-162b2)

Indication

- Investigational (Not approved by U.S. FDA)
- Authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age and older.

• Dosing and Schedule

- Administer intramuscularly as a series of two doses (0.3 mL each) 3 weeks apart

• Vaccine Storage (See EAU Fact Sheet* for Details)

- Cartons arrive in thermal containers on dry ice
- Thermal container maintains a temperature range of -90°C to -60°C (-130°F to -76°F)
- Vials require storage in ultra-low temperature freezer at -80°C to -60°C (-112°F to -76°F)
- Vials require protection from light until ready to use
- Thaw and store undiluted vials in refrigerator at 2°C to 8°C (35°F to 46°F)] for up to 5 days (120 hours)
- For immediate use, thaw undiluted vials at room temperature [up to 25°C (77°F)] for 30 minutes
- After dilution, store vials between 2°C to 25°C (35°F to 77°F) and use ≤6 hours from time of dilution; do not refreeze




Slides WITHOUT Text




DNA versus RNA

Deoxyribonucleic acid (DNA) Ribonucleic acid (RNA)






Basic Flow of Genetic Information for Protein Formation in Humans







Ribosome Structure and Function






Types of RNA








SARS-CoV-2 Virus Structure






COVID-19 mRNA Vaccines






COVID-19 mRNA Vaccines






COVID-19 mRNA Vaccine Delivery






Moderna COVID-19 Vaccine (mRNA-1273): Mechanism of Action






Pfizer-BioNTech COVID-19 Vaccine (BNT162b2): Mechanism of Action





Immune Response to COVID-19 mRNA Vaccines





Moderna COVID-19 Vaccine (mRNA-1273)

Indication

- Investigational (Not approved by U.S. FDA)
- Authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) in individuals 18 years of age and older

Dosing and Schedule

- Administer intramuscularly as a series of two doses (0.5 mL each) 1 month apart

Vaccine Storage

- Multiple-dose vials are stored frozen between -25° to -15°C (-13° to 5°F)
- Do not store on dry ice or at temperatures below -40°C
- Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use
- Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours
- After first dose withdrawn, keep vial between 2° to 25°C (36° to 77°F) and discard vial after 6 hours

Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)

Indication

- Investigational (Not approved by U.S. FDA)
- Authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age and older.

• Dosing and Schedule

- Administer intramuscularly as a series of two doses (0.3 mL each) 3 weeks apart

Vaccine Storage (See EAU Fact Sheet* for Details)

- Cartons arrive in thermal containers on dry ice
- Thermal container maintains a temperature range of -90°C to -60°C (-130°F to -76°F).
- Vials require storage in ultra-low temperature freezer at -80°C to -60°C (-112°F to -76°F)
- Thaw and store undiluted vials in refrigerator [2°C to 8°C (35°F to 46°F)] for up to 5 days (120 hours)
- For immediate use, thaw undiluted vials at room temperature [up to 25°C (77°F)] for 30 minutes
- After dilution, store vials between 2°C to 25°C (35°F to 77°F) and use ≤6 hours from time of dilution